CCR5 and CXCR4 usage by non-clade B human immunodeficiency virus type 1 primary isolates

Journal of Virology

Volumn 76, Issue 6, 2002, Pages 3059-3064

  Thompson, Daniah A D ^a   Cormier, Emmanuel G ^a   Dragic, Tatjana ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; GLYCOPROTEIN GP 120; TYROSINE;

AMINO TERMINAL SEQUENCE; ARTICLE; CLADISTICS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; RECEPTOR BINDING; VIRUS CELL INTERACTION; VIRUS INCLUSION; VIRUS ISOLATION; VIRUS MORPHOGENESIS;

AMINO ACID SEQUENCE; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; RECEPTORS, CCR5; RECEPTORS, CXCR4;

EID: 0036187934     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.76.6.3059-3064.2002     Document Type: Article

References (41)

1. Patterns of CCR5, CXCR4, and CCR3 usage by envelope glycoproteins from human immunodeficiency virus type 1 primary isolates
2. The CCR5 deletion mutation fails to protect against multiple sclerosis
3. HIV entry and tropism: The chemokine receptor expression
4. Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease
5. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype
6. Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS patients
7. Multiple charged and aromatic residues in CCR5 amino-terminal domain are involved in high affinity binding of both chemokines and HIV-1 env protein
8. Effect of mutations in the second extracellular loop of CXCR4 on its utilization by human and feline immunodeficiency viruses
9. Identification of residues of CXCR4 critical for human immunodeficiency virus coreceptor and chemokine receptor activities
10. Absence of coreceptor switch with disease progression in human immunodeficiency virus infections in India
11. Mutagenesis of CXCR4 identifies important domains for human immunodeficiency virus type 1 X4 isolate envelope-mediated membrane fusion and virus entry and reveals cryptic coreceptor activity for R5 isolates
12. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals
13. Specific interaction of CCR5 amino-terminal domain peptides containing sulfo-tyrosines with HIV-1 envelope glycoprotein gp120
14. Mapping the determinants of the CCR5 amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes
15. Association between CCR5 genotype and the clinical course of HIV-1 infection
16. Adaptation to promiscuous usage of chemokine receptors is not a prerequisite for human immunodeficiency virus type 1 disease progression
17. Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1
18. An overview of the determinants of CCR5 and CXCR4 co-receptor function
19. Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry
20. A tyrosinerich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5
21. Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G
22. A comprehensive panel of near-full-length clones and reference sequences for non-subtype B isolates of human immunodeficiency virus type 1
23. The heterosexual human immunodeficiency virus type 1 epidemic in Thailand is caused by an intersubtype (A/E) recombinant of African origin
24. CCR5-mediated human immunodeficiency virus entry depends on an amino-terminal gp120-binding site and on the conformational integrity of all four extracellular domains
25. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression
26. Analysis of the critical domain in the V3 loop of human immunodeficiency virus type 1 gp120 involved in CCR5 utilization
27. Entry of R5X4 and X4 human immunodeficiency virus type 1 strains is mediated by negatively charged and tyrosine residues in the amino-terminal domain and the second extracellular loop of CXCR4
28. Polymorphisms in the CCR5 genes of African green monkeys and mice implicate specific amino acids in infections by simian and human immunodeficiency viruses
29. Persistent CCR5 utilization and enhanced macrophage tropism by primary blood human immunodeficiency virus type 1 isolates from advanced stages of disease and comparison to tissue-derived isolates
30. Early protective effect of CCR-5 delta 32 heterozygosity on HIV-1 disease progression: Relationship with viral load
31. The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression
32. Alanine substitutions of polar and nonpolar residues in the amino-terminal domain of CCR5 differently impair entry of macrophage- and dualtropic isolates of human immunodeficiency virus type 1
33. Multiple residues contribute to the inability of murine CCR-5 to function as a coreceptor for macrophage-tropic human immunodeficiency virus type 1 isolates
34. Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry
35. Differences in chemokine coreceptor usage between genetic subtypes of HIV-1
36. Coreceptor usage of HIV-1 isolates representing different genetic subtypes obtained from pregnant Cameroonian women
37. CCR5 coreceptor usage of non-syncytium-inducing primary HIV-1 is independent of phylogenetically distinct global HIV-1 isolates: Delineation of consensus motif in the V3 domain that predicts CCR-5 usage
38. Human immunodeficiency virus type 1 clade A and D neurotropism: Molecular evolution, recombination, and coreceptor use
39. Chemokine coreceptor usage by diverse primary isolates of human immunodeficiency virus type 1
40. Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells
41. Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus type 1 entry?